
Clinical Trials - September 15, 2020
Albireo trial meets primary endpoints
Albireo Pharma has announced positive results from PEDFIC 1, a global Phase 3 clinical trial evaluating the efficacy and safety of odevixibat and the largest study ever conducted in PFIC1 and PFIC2. PEDFIC 1 met its two primary endpoints, demonstrating that odevixibat reduced serum bile acid responses (sBAs) (p=0.003) and improved pruritus assessments (p=0.004) with […]

Pharma Business - September 28, 2015
Albireo opens office in the US
Albireo, a company focused through its operating subsidiary on the development of bile acid modulators to treat orphan pediatric and adult liver diseases, NASH, and gastrointestinal disorders, has announced that Ron Cooper has joined the company as President and Chief Executive Officer. In addition, Albireo has established a US subsidiary office in Boston, Massachusetts. Mr. Cooper […]